Renaissance Group LLC Cuts Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Renaissance Group LLC cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 5.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 349,741 shares of the company's stock after selling 20,167 shares during the quarter. Renaissance Group LLC's holdings in Teva Pharmaceutical Industries were worth $7,740,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Diversify Advisory Services LLC raised its position in Teva Pharmaceutical Industries by 2.5% during the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after acquiring an additional 496 shares during the period. Sanctuary Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries by 1.9% during the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after purchasing an additional 664 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of Teva Pharmaceutical Industries by 0.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after purchasing an additional 699 shares during the last quarter. Metis Global Partners LLC raised its position in shares of Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after purchasing an additional 860 shares during the last quarter. Finally, DGS Capital Management LLC lifted its stake in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock valued at $246,000 after buying an additional 872 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Teva Pharmaceutical Industries Trading Up 4.7 %

Teva Pharmaceutical Industries stock traded up $0.60 during midday trading on Friday, hitting $13.42. 12,222,912 shares of the stock were exchanged, compared to its average volume of 9,917,801. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock has a market capitalization of $15.22 billion, a price-to-earnings ratio of -9.26, a PEG ratio of 1.44 and a beta of 0.72. The stock's 50-day simple moving average is $15.79 and its 200 day simple moving average is $17.82. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on TEVA shares. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Friday, April 4th. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Finally, Bank of America lowered their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.